Response to letter entitled: Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer".

[1]  G. Viale,et al.  Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status , 2022, Virchows Archiv.

[2]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[3]  Yan Song,et al.  Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer , 2022, Laboratory Investigation.

[4]  M. Lacroix-Triki,et al.  LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial , 2022, Annals of Oncology.

[5]  L. Pusztai,et al.  Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. , 2022, JAMA oncology.

[6]  C. Criscitiello,et al.  Evolution of low HER2 expression between early and advanced-stage breast cancer. , 2022, European journal of cancer.

[7]  Michel E. Vandenberghe,et al.  Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay. , 2021 .

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  C. Redfern,et al.  Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.